Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells

Resistance mechanisms are being defined for CAR T cells. Tumor cells emerging after GPRC5D CAR T-cell therapy could have decreased or lost expression of the GPRC5D target through biallelic gene loss or transcriptional down-regulation.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-10, Vol.389 (15), p.1435-1437
Hauptverfasser:	Mi, Xiaoli, Penson, Alex, Abdel-Wahab, Omar, Mailankody, Sham
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens Biopsy Bone marrow Cancer Cell therapy Chromosomes Gene regulation Genetics Hematology Humans Immunity Immunotherapy, Adoptive Leukemia Lymphocytes Lymphocytes T Lymphoma Multiple myeloma Multiple Myeloma - genetics Multiple Myeloma - immunology Multiple Myeloma - therapy Neoplasm Recurrence, Local Oncology Patients Protein expression Proteins Receptors, Chimeric Antigen Receptors, G-Protein-Coupled - genetics Recurrence T-Lymphocytes Treatments in Oncology Tumor cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Resistance mechanisms are being defined for CAR T cells. Tumor cells emerging after GPRC5D CAR T-cell therapy could have decreased or lost expression of the GPRC5D target through biallelic gene loss or transcriptional down-regulation.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMc2308544